Paid Plans
Want to analyze multiple companies at once? Paid plans let you compare up to 5 stocks side by side.
Sign Up
ZLD
vs
S
S&P/ASX 300
ZLD
Over the past 12 months, ZLD has significantly outperformed S&P/ASX 300, delivering a return of +47% compared to S&P/ASX 300's +4% growth.
Stocks Performance
ZLD vs S&P/ASX 300
Performance Gap
ZLD vs S&P/ASX 300
Create a free account · No card needed
Performance By Year
ZLD vs S&P/ASX 300
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
Zelira Therapeutics Ltd
Glance View
Zelira Therapeutics Ltd. is a bio-pharmaceutical company, which engages in the research, development and commercialisation of cannabinoid-based formulations for the treatment of a variety of medical conditions. The firm is engaged in the research, development and commercialization of clinically validated cannabinoid-based medicines. The company owns a portfolio of products and a pipeline of candidates undergoing clinical development positioned to enter global markets. The company is focused on developing and clinically validating branded cannabinoid-based medicines in its prescription (Rx) business for the treatment of a variety of medical conditions, including insomnia, autism and chronic non-cancer pain, as well as offering over the counter (OTC) products. The company has two medications: HOPE and ZENIVOL. ZENIVOL is a cannabinoid-based medicine for the treatment of chronic insomnia. The firm in partnership with SprinJeneCBD, introduced a full line of oral care products, including SprinJeneCBD toothpaste product, which is a hemp-derived, oral care products containing cannabinoids, blackseed oil and zinc utilizing patented technology.
Create a free account · No card needed
